April 2022

April 28, 2022

Acute graft-versus-host disease (aGVHD) is the most frequently encountered, life- threatening complication following an allogeneic hematopoietic stem cell transplant (aHSCT).

April 27, 2022

Two-thirds of women diagnosed with endometrial cancer have localized disease and a 5-year relative survival of 95%.

April 26, 2022

An expert panel engaged the audience in a live virtual symposium and case discussion on immune checkpoint inhibitors (ICIs) in the first-line treatment of non−small cell lung cancer (NSCLC) at the 2021 ASHP Midyear Clinical Meeting.

April 25, 2022

Attendees of this live virtual program learned the latest and greatest in a presentation from 2 expert oncology pharmacists.

April 22, 2022

In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

April 21, 2022

The agent is the first oral therapy for this indication.

April 20, 2022

Asciminib offers a new option for patients harboring the T315I mutation.

April 19, 2022

The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.

April 18, 2022

New therapies and combination regimens may allow a more tailored approach.

April 14, 2022

Numbers have remained below prepandemic levels.

April 13, 2022

Biosimilars could save consumers more than $100 billion in the coming years.

April 12, 2022

Cutaneous squamous cell carcinoma should be diagnosed early and treated promptly to avoid complications.

April 11, 2022

A variety of strategies can help increase patient adherence to oral chemotherapy.

April 04, 2022

Oncology and specialty treatments advance alongside care.

April 01, 2022

We see today far more clearly the impact of health care inequality, which can directly affect patient access to care, specifically oncologic care.